Lipidor Ab
Lipidor AB (publ), a pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, acne vulgaris, bacterial skin infections, and atopic dermatitis. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, AKP-03 for bacterial skin diseases, and AKP-07 for atopic dermat… Read more
Lipidor Ab (LIPI) - Total Liabilities
Latest total liabilities as of December 2024: Skr3.86 Million SEK
Based on the latest financial reports, Lipidor Ab (LIPI) has total liabilities worth Skr3.86 Million SEK as of December 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Lipidor Ab - Total Liabilities Trend (2016–2024)
This chart illustrates how Lipidor Ab's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Lipidor Ab Competitors by Total Liabilities
The table below lists competitors of Lipidor Ab ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Inch Kenneth Kajang Rubber PLC
KLSE:2607
|
Malaysia | RM122.86 Million |
|
Coal Energy S.A.
WAR:CLE
|
Poland | zł3.50 Million |
|
24SevenOffice Scandinavia AB
ST:247
|
Sweden | Skr109.79 Million |
|
Workhorse Group Inc
NASDAQ:WKHS
|
USA | $84.67 Million |
|
Soligenix Inc.
NASDAQ:SNGX
|
USA | $3.70 Million |
|
Luo Lih Fen Holding Co Ltd
TW:6666
|
Taiwan | NT$536.22 Million |
|
K Seng Seng Corporation Bhd
KLSE:5192
|
Malaysia | RM133.85 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Lipidor Ab's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lipidor Ab's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lipidor Ab (2016–2024)
The table below shows the annual total liabilities of Lipidor Ab from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr3.86 Million | -68.27% |
| 2023-12-31 | Skr12.16 Million | -9.74% |
| 2022-12-31 | Skr13.47 Million | +17.22% |
| 2021-12-31 | Skr11.49 Million | +417.33% |
| 2020-12-31 | Skr2.22 Million | +50.95% |
| 2019-12-31 | Skr1.47 Million | -60.60% |
| 2018-12-31 | Skr3.74 Million | +239.33% |
| 2017-12-31 | Skr1.10 Million | -34.73% |
| 2016-12-31 | Skr1.69 Million | -- |